GOAL trial: Rescue treatment with the monoclonal anti CD20-antibody Obinutuzumab (GA101) in combination with PixantrOne for the treatment of patients with relapsed Aggressive B-cell Lymphoma

Trial Profile

GOAL trial: Rescue treatment with the monoclonal anti CD20-antibody Obinutuzumab (GA101) in combination with PixantrOne for the treatment of patients with relapsed Aggressive B-cell Lymphoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Obinutuzumab (Primary) ; Pixantrone (Primary)
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma
  • Focus Therapeutic Use
  • Acronyms GOAL
  • Most Recent Events

    • 06 Dec 2016 Results (n=24) assessing safety and efficacy presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 14 Aug 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 05 Aug 2015 Planned initiation date changed from 1 Jul 2015 to 1 Aug 2015, as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top